Indian data on central nervous tumors: A summary of published work

Archya Dasgupta; Tejpal Gupta; Rakesh Jalali

doi:10.4103/2278-330X.187589

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Review Article

05 (

); 147-153

doi:

10.4103/2278-330X.187589

Indian data on central nervous tumors: A summary of published work

Archya Dasgupta¹, Tejpal Gupta¹, Rakesh Jalali^1,

1 Department of Radiation Oncology, Neuro-Oncology Group, Tata Memorial Hospital, Mumbai, Maharashtra

*Corresponding author: Dr. Rakesh Jalali. rjalali@tmc.gov.in

Published: 2020-12-28

MedIntel Services Pvt Ltd. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

Disclaimer:
This article was originally published by Thieme Medical and Scientific Publishers Pvt. Ltd. and was migrated to Scientific Scholar after the change of Publisher.

Abstract

Tumors of the central nervous system (CNS) constitute approximately 2% of all malignancies. Although relatively rare, the associated morbidity and mortality and the significant proportion of affected young and middle-aged individuals has a major bearing on the death-adjusted life years compared to other malignancies. CNS tumors encompass a very broad spectrum with regards to age, location, histology, and clinical outcomes. Advances in diagnostic imaging, surgical techniques, radiotherapy equipment, and generation of newer chemotherapeutic and targeted agents over the past few years have helped improving treatment outcome. Further insights into the molecular pathways leading to the development of tumors made in the past decade are being incorporated into routine clinical practice. Several focused groups within India have been working on a range of topics related to CNS tumors, and a significant body of work from India, in the recent years, is being increasingly recognized throughout the world. The present article summarizes key published work with particular emphasis on gliomas and medulloblastoma, the two commonly encountered tumors.

Keywords

References

Nair M, Varghese C, Swaminathan R. Cancer: Current Scenario, Intervention Strategies and Projections for 2015. NCMH Background Papers; 2015.
Yeole BB. Trends in the brain cancer incidence in India. Asian Pac J Cancer Prev 2008;9:267-70.
Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol 2008;87:111-4.
Jain A, Sharma MC, Suri V, Kale SS, Mahapatra AK, Tatke M, et al. Spectrum of pediatric brain tumors in India: A multi-institutional study. Neurol India 2011;59:208-11.
Asirvatham JR, Deepti AN, Chyne R, Prasad MS, Chacko AG, Rajshekhar V, et al. Pediatric tumors of the central nervous system: A retrospective study of 1,043 cases from a tertiary care center in South India. Childs Nerv Syst 2011;27:1257-63.
Shastry AH, Thota B, Srividya MR, Arivazhagan A, Santosh V. Nuclear protein phosphatase 1 α (PP1A) expression is associated with poor prognosis in p53 expressing glioblastomas. Pathol Oncol Res 2016;22:287-92.
Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17438.
Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, Shailaja BC, et al. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group. PLoS One 2013;8:e62042.
Irshad K, Mohapatra SK, Srivastava C, Garg H, Mishra S, Dikshit B, et al. A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLoS One 2015;10:e0118201.
Nijaguna MB, Patil V, Urbach S, Shwetha SD, Sravani K, Hegde AS, et al. Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding protein 1 (IGFBP1) to promote angiogenesis. J Biol Chem 2015;290:23401-15.
Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA, et al. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One 2013;8:e63164.
Jha P, Suri V, Singh G, Jha P, Purkait S, Pathak P, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 2011;20:225-32.
Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, et al. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011;31:376-83.
Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011;18:66-70.
Jha P, Suri V, Sharma V, Singh G, Sharma MC, Pathak P, et al. IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011;91:385-93.
Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhagan A, Thennarasu K, et al. IDH1 mutations in diffusely infiltrating astrocytomas: Grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol 2012;138:177-84.
Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005;24:7073-83.
Rao SA, Srinivasan S, Patric IR, Hegde AS, Chandramouli BA, Arimappamagan A, et al. A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One 2014;9:e85200.
Roy B, Awasthi R, Bindal A, Sahoo P, Kumar R, Behari S, et al. Comparative evaluation of 3-dimensional pseudocontinuous arterial spin labeling with dynamic contrast-enhanced perfusion magnetic resonance imaging in grading of human glioma. J Comput Assist Tomogr 2013;37:321-6.
Goda JS, Dutta D, Raut N, Juvekar SL, Purandare N, Rangarajan V, et al. Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study. Pediatr Neurosurg 2013;49:274-81.
Santra A, Sharma P, Kumar R, Bal C, Kumar A, Julka PK, et al. Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced MRI in detection of recurrent glioma. Nucl Med Commun 2011;32:206-11.
Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT. Clin Nucl Med 2011;36:650-5.
Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, et al. F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur J Radiol 2012;81:508-13.
Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S, et al. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol 2014;83:219-25.
Khangembam BC, Karunanithi S, Sharma P, Kc SS, Kumar R, Julka PK, et al. Perfusion-metabolism coupling in recurrent gliomas: A prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. Neuroradiology 2014;56:893-902.
Moiyadi AV, Shetty PM, Mahajan A, Udare A, Sridhar E. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien) 2013;155:2217-25.
Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, et al. Encouraging experience of concomitant temozolomide with radiotherapy followed by adjuvant temozolomide in newly diagnosed glioblastoma multiforme: Single institution experience. Br J Neurosurg 2007;21:583-7.
Anand AK, Chaudhory AR, Aggarwal HN, Sachdeva PK, Negi PS, Sinha SN, et al. Survival outcome and neurotoxicity in patients of high-grade gliomas treated with conformal radiation and temozolamide. J Cancer Res Ther 2012;8:50-6.
Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R, et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. J Neurosci Rural Pract 2013;4 Suppl 1:S46-55.
Julka PK, Sharma DN, Mallick S, Gandhi AK, Joshi N, Rath GK. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide: A mono-institutional experience of 215 patients. J Cancer Res Ther 2013;9:381-6.
Gupta T, Dutta D, Trivedi S, Upasani M, Jalali R, Sarin R. Assessment of compliance to treatment and efficacy of a resource-sparing hypofractionated radiotherapy regimen in patients with poor-prognosis high-grade gliomas. J Cancer Res Ther 2010;6:272-7.
Singh G, Mallick S, Sharma V, Joshi N, Purkait S, Jha P, et al. A study of clinico-pathological parameters and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. Neuropathology 2012;32:534-42.
Kumar N, Bhattacharyya T, Chanchalani K, Shalunke P, Radotra BD, Yadav BS. Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. South Asian J Cancer 2015;4:15-7.
Goda JS, Lewis S, Agarwal A, Epari S, Churi S, Padmavati A, et al. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma? Clin Neurol Neurosurg 2015;135:46-53.
Mallick S, Gandhi AK, Joshi NP, Kumar A, Puri T, Sharma DN, et al. Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors. Indian J Med Paediatr Oncol 2015;36:99-104.
Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2010;77:113-8.
Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: Feasibility and perioperative outcomes. Neurol India 2012;60:185-90.
Anand AK, Kumar P, Patir R, Vaishya S, Bansal AK, Chaudhoory AR, et al. Fractionated stereotactic radiosurgery with volumetric modulated arc therapy (Rapid Arc) for reradiation in recurrent high grade gliomas. J Cancer Res Ther 2014;10:97-102.
Gupta T, Mohanty S, Moiyadi A, Jalali R. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: A clinical audit. Clin Neurol Neurosurg 2013;115:1814-9.
Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100-8.
Jalali R, Julka PK, Anand AK, Bhavsar D, Singhal N, Naik R, et al. An open label, prospective, multicentric study to evaluate the safety and efficacy of BIOMAb-EGFR TM (Nimotuzumab) as induction and maintenance therapy in combination with radiotherapy plus temozolomide (Concomitant & Adjuvant) in Indian patients with glioblastoma multiforme. Neuro Oncology 2011;13;iii57.
Gupta T, Nair V, Paul SN, Kannan S, Moiyadi A, Epari S, et al. Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma? J Neurooncol 2012;109:195-203.
Gupta T, Sarin R, Jalali R, Sharma S, Kurkure P, Goel A. A pragmatic clinicopathobiological grouping/staging system for gliomas: Proposal of the Indian TNM subcommittee on brain tumors. Neurol India 2009;57:247-51.
Gupta T, Nair V, Epari S, Pietsch T, Jalali R. Concordance between local, institutional, and central pathology review in glioblastoma: Implications for research and practice: A pilot study. Neurol India 2012;60:61-5.
Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-9.
Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80.
Jha P, Pia Patric IR, Shukla S, Pathak P, Pal J, Sharma V, et al. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro Oncol 2014;16:1607-17.
Jha P, Agrawal R, Pathak P, Kumar A, Purkait S, Mallik S, et al. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs. Int J Cancer 2015;137:2343-53.
Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, et al. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India 2009;57:559-66.
Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, et al. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 2011;13:1099-106.
Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, et al. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 2015;208:91-5.
Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol 2013;15:1644-51.
Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 2010;6:521-9.
Yogi K, Sridhar E, Goel N, Jalali R, Goel A, Moiyadi A, et al. MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting neuropilin 1. Oncoscience 2015;2:334-48.
Panwalkar P, Moiyadi A, Goel A, Shetty P, Goel N, Sridhar E, et al. MiR-206, a cerebellum enriched miRNA is downregulated in all medulloblastoma subgroups and its overexpression is necessary for growth inhibition of medulloblastoma cells. J Mol Neurosci 2015;56:673-80.
Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, Gupta D, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: A simplified approach. Brain Pathol 2016;26:334-43.
Dasgupta A, Gupta T, Pungavkar S, Shirsat N, Mahajan A, Janu A, et al. Combined clinical parameters with specific MRI features yield highly accurate prediction of medulloblastoma subtypes: Data from 72 patients in a blinded study. Neuro Oncology 2016;18:iii104-iii105.
Muzumdar D, Deshpande A, Kumar R, Sharma A, Goel N, Dange N, et al. Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients. J Pediatr Neurosci 2011;6 Suppl 1:S78-85.
Menon G, Krishnakumar K, Nair S. Adult medulloblastoma: Clinical profile and treatment results of 18 patients. J Clin Neurosci 2008;15:122-6.
Gupta T, Jalali R, Goswami S, Nair V, Moiyadi A, Epari S, et al. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:1534-40.
Gupta T, Mohanty S, Kannan S, Jalali R. Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma. Neurooncol Pract 2014;1:86-93.
Biswas A, Julka PK, Bakhshi S, Suri A, Rath GK. Intracranial atypical teratoid rhabdoid tumor: Current management and a single institute experience of 15 patients from North India. Acta Neurochir (Wien) 2015;157:589-96.
Biswas A, Mallick S, Purkait S, Roy S, Sarkar C, Bakhshi S, et al. Treatment outcome and patterns of failure in patients of non-pineal supratentorial primitive neuroectodermal tumor: Review of literature and clinical experience form a regional cancer center in North India. Acta Neurochir (Wien) 2015;157:1251-66.
Biswas A, Mallick S, Purkait S, Gandhi A, Sarkar C, Singh M, et al. Treatment outcome and patterns of failure in patients of pinealoblastoma: Review of literature and clinical experience from a regional cancer centre in North India. Childs Nerv Syst 2015;31:1291-304.
Jalali R, Gupta T, Goswami S, Golambade N, Shah N, Sarin R. Detailed Neuropsychological, Activity of Daily Living and Endocrine Function Assessment in Children with Craniopharyngioma Treated with High Precision Focal Radiotherapy: Data from a Prospective Trial. ISPNO; 2011.
Jalali R, Dutta D, Kamble R, Gupta T, Munshi A, Sarin R, et al. Prospective assessment of activities of daily living using modified Barthel′s index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. J Neurooncol 2008;90:321-8.
Dutta D, Vanere P, Gupta T, Munshi A, Jalali R. Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: Results from a prospective study. J Neurooncol 2009;94:103-10.
Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol 2009;95:413-9.
Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, et al. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:974-9.

Fulltext Views
15

PDF downloads
3

View/Download PDF
Download Citations

BibTeX
RIS

Show Sections

[1] Nair M, Varghese C, Swaminathan R. Cancer: Current Scenario, Intervention Strategies and Projections for 2015. NCMH Background Papers; 2015.

[2] Yeole BB. Trends in the brain cancer incidence in India. Asian Pac J Cancer Prev 2008;9:267-70.

[3] Jalali R, Datta D. Prospective analysis of incidence of central nervous tumors presenting in a tertiary cancer hospital from India. J Neurooncol 2008;87:111-4.

[4] Jain A, Sharma MC, Suri V, Kale SS, Mahapatra AK, Tatke M, et al. Spectrum of pediatric brain tumors in India: A multi-institutional study. Neurol India 2011;59:208-11.

[5] Asirvatham JR, Deepti AN, Chyne R, Prasad MS, Chacko AG, Rajshekhar V, et al. Pediatric tumors of the central nervous system: A retrospective study of 1,043 cases from a tertiary care center in South India. Childs Nerv Syst 2011;27:1257-63.

[6] Shastry AH, Thota B, Srividya MR, Arivazhagan A, Santosh V. Nuclear protein phosphatase 1 α (PP1A) expression is associated with poor prognosis in p53 expressing glioblastomas. Pathol Oncol Res 2016;22:287-92.

[7] Srinivasan S, Patric IR, Somasundaram K. A ten-microRNA expression signature predicts survival in glioblastoma. PLoS One 2011;6:e17438.

[8] Arimappamagan A, Somasundaram K, Thennarasu K, Peddagangannagari S, Srinivasan H, Shailaja BC, et al. A fourteen gene GBM prognostic signature identifies association of immune response pathway and mesenchymal subtype with high risk group. PLoS One 2013;8:e62042.

[9] Irshad K, Mohapatra SK, Srivastava C, Garg H, Mishra S, Dikshit B, et al. A combined gene signature of hypoxia and notch pathway in human glioblastoma and its prognostic relevance. PLoS One 2015;10:e0118201.

[10] Nijaguna MB, Patil V, Urbach S, Shwetha SD, Sravani K, Hegde AS, et al. Glioblastoma-derived macrophage colony-stimulating factor (MCSF) induces microglial release of insulin-like growth factor-binding protein 1 (IGFBP1) to promote angiogenesis. J Biol Chem 2015;290:23401-15.

[11] Rao SA, Arimappamagan A, Pandey P, Santosh V, Hegde AS, Chandramouli BA, et al. miR-219-5p inhibits receptor tyrosine kinase pathway by targeting EGFR in glioblastoma. PLoS One 2013;8:e63164.

[12] Jha P, Suri V, Singh G, Jha P, Purkait S, Pathak P, et al. Characterization of molecular genetic alterations in GBMs highlights a distinctive molecular profile in young adults. Diagn Mol Pathol 2011;20:225-32.

[13] Srividya MR, Thota B, Shailaja BC, Arivazhagan A, Thennarasu K, Chandramouli BA, et al. Homozygous 10q23/PTEN deletion and its impact on outcome in glioblastoma: A prospective translational study on a uniformly treated cohort of adult patients. Neuropathology 2011;31:376-83.

[14] Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, et al. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 2011;18:66-70.

[15] Jha P, Suri V, Sharma V, Singh G, Sharma MC, Pathak P, et al. IDH1 mutations in gliomas: First series from a tertiary care centre in India with comprehensive review of literature. Exp Mol Pathol 2011;91:385-93.

[16] Thota B, Shukla SK, Srividya MR, Shwetha SD, Arivazhagan A, Thennarasu K, et al. IDH1 mutations in diffusely infiltrating astrocytomas: Grade specificity, association with protein expression, and clinical relevance. Am J Clin Pathol 2012;138:177-84.

[17] Somasundaram K, Reddy SP, Vinnakota K, Britto R, Subbarayan M, Nambiar S, et al. Upregulation of ASCL1 and inhibition of Notch signaling pathway characterize progressive astrocytoma. Oncogene 2005;24:7073-83.

[18] Rao SA, Srinivasan S, Patric IR, Hegde AS, Chandramouli BA, Arimappamagan A, et al. A 16-gene signature distinguishes anaplastic astrocytoma from glioblastoma. PLoS One 2014;9:e85200.

[19] Roy B, Awasthi R, Bindal A, Sahoo P, Kumar R, Behari S, et al. Comparative evaluation of 3-dimensional pseudocontinuous arterial spin labeling with dynamic contrast-enhanced perfusion magnetic resonance imaging in grading of human glioma. J Comput Assist Tomogr 2013;37:321-6.

[20] Goda JS, Dutta D, Raut N, Juvekar SL, Purandare N, Rangarajan V, et al. Can multiparametric MRI and FDG-PET predict outcome in diffuse brainstem glioma? A report from a prospective phase-II study. Pediatr Neurosurg 2013;49:274-81.

[21] Santra A, Sharma P, Kumar R, Bal C, Kumar A, Julka PK, et al. Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced MRI in detection of recurrent glioma. Nucl Med Commun 2011;32:206-11.

[22] Santra A, Kumar R, Sharma P, Bal C, Julka PK, Malhotra A. Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and F-18 FDG PET/CT. Clin Nucl Med 2011;36:650-5.

[23] Santra A, Kumar R, Sharma P, Bal C, Kumar A, Julka PK, et al. F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur J Radiol 2012;81:508-13.

[24] Karunanithi S, Sharma P, Kumar A, Gupta DK, Khangembam BC, Ballal S, et al. Can (18)F-FDOPA PET/CT predict survival in patients with suspected recurrent glioma? A prospective study. Eur J Radiol 2014;83:219-25.

[25] Khangembam BC, Karunanithi S, Sharma P, Kc SS, Kumar R, Julka PK, et al. Perfusion-metabolism coupling in recurrent gliomas: A prospective validation study with 13N-ammonia and 18F-fluorodeoxyglucose PET/CT. Neuroradiology 2014;56:893-902.

[26] Moiyadi AV, Shetty PM, Mahajan A, Udare A, Sridhar E. Usefulness of three-dimensional navigable intraoperative ultrasound in resection of brain tumors with a special emphasis on malignant gliomas. Acta Neurochir (Wien) 2013;155:2217-25.

[27] Jalali R, Basu A, Gupta T, Munshi A, Menon H, Sarin R, et al. Encouraging experience of concomitant temozolomide with radiotherapy followed by adjuvant temozolomide in newly diagnosed glioblastoma multiforme: Single institution experience. Br J Neurosurg 2007;21:583-7.

[28] Anand AK, Chaudhory AR, Aggarwal HN, Sachdeva PK, Negi PS, Sinha SN, et al. Survival outcome and neurotoxicity in patients of high-grade gliomas treated with conformal radiation and temozolamide. J Cancer Res Ther 2012;8:50-6.

[29] Kumar N, Kumar P, Angurana SL, Khosla D, Mukherjee KK, Aggarwal R, et al. Evaluation of outcome and prognostic factors in patients of glioblastoma multiforme: A single institution experience. J Neurosci Rural Pract 2013;4 Suppl 1:S46-55.

[30] Julka PK, Sharma DN, Mallick S, Gandhi AK, Joshi N, Rath GK. Postoperative treatment of glioblastoma multiforme with radiation therapy plus concomitant and adjuvant temozolomide: A mono-institutional experience of 215 patients. J Cancer Res Ther 2013;9:381-6.

[31] Gupta T, Dutta D, Trivedi S, Upasani M, Jalali R, Sarin R. Assessment of compliance to treatment and efficacy of a resource-sparing hypofractionated radiotherapy regimen in patients with poor-prognosis high-grade gliomas. J Cancer Res Ther 2010;6:272-7.

[32] Singh G, Mallick S, Sharma V, Joshi N, Purkait S, Jha P, et al. A study of clinico-pathological parameters and O6-methylguanine DNA methyltransferase (MGMT) promoter methylation status in the prognostication of gliosarcoma. Neuropathology 2012;32:534-42.

[33] Kumar N, Bhattacharyya T, Chanchalani K, Shalunke P, Radotra BD, Yadav BS. Impact of changing trends of treatment on outcome of cerebral gliosarcoma: A tertiary care centre experience. South Asian J Cancer 2015;4:15-7.

[34] Goda JS, Lewis S, Agarwal A, Epari S, Churi S, Padmavati A, et al. Impact of oligodendroglial component in glioblastoma (GBM-O): Is the outcome favourable than glioblastoma? Clin Neurol Neurosurg 2015;135:46-53.

[35] Mallick S, Gandhi AK, Joshi NP, Kumar A, Puri T, Sharma DN, et al. Outcomes of pediatric glioblastoma treated with adjuvant chemoradiation with temozolomide and correlation with prognostic factors. Indian J Med Paediatr Oncol 2015;36:99-104.

[36] Jalali R, Raut N, Arora B, Gupta T, Dutta D, Munshi A, et al. Prospective evaluation of radiotherapy with concurrent and adjuvant temozolomide in children with newly diagnosed diffuse intrinsic pontine glioma. Int J Radiat Oncol Biol Phys 2010;77:113-8.

[37] Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: Feasibility and perioperative outcomes. Neurol India 2012;60:185-90.

[38] Anand AK, Kumar P, Patir R, Vaishya S, Bansal AK, Chaudhoory AR, et al. Fractionated stereotactic radiosurgery with volumetric modulated arc therapy (Rapid Arc) for reradiation in recurrent high grade gliomas. J Cancer Res Ther 2014;10:97-102.

[39] Gupta T, Mohanty S, Moiyadi A, Jalali R. Factors predicting temozolomide induced clinically significant acute hematologic toxicity in patients with high-grade gliomas: A clinical audit. Clin Neurol Neurosurg 2013;115:1814-9.

[40] Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, et al. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): A multicentre, randomised, open-label, phase 3 trial. Lancet Oncol 2014;15:1100-8.

[41] Jalali R, Julka PK, Anand AK, Bhavsar D, Singhal N, Naik R, et al. An open label, prospective, multicentric study to evaluate the safety and efficacy of BIOMAb-EGFR TM (Nimotuzumab) as induction and maintenance therapy in combination with radiotherapy plus temozolomide (Concomitant & Adjuvant) in Indian patients with glioblastoma multiforme. Neuro Oncology 2011;13;iii57.

[42] Gupta T, Nair V, Paul SN, Kannan S, Moiyadi A, Epari S, et al. Can irradiation of potential cancer stem-cell niche in the subventricular zone influence survival in patients with newly diagnosed glioblastoma? J Neurooncol 2012;109:195-203.

[43] Gupta T, Sarin R, Jalali R, Sharma S, Kurkure P, Goel A. A pragmatic clinicopathobiological grouping/staging system for gliomas: Proposal of the Indian TNM subcommittee on brain tumors. Neurol India 2009;57:247-51.

[44] Gupta T, Nair V, Epari S, Pietsch T, Jalali R. Concordance between local, institutional, and central pathology review in glioblastoma: Implications for research and practice: A pilot study. Neurol India 2012;60:61-5.

[45] Ganigi PM, Santosh V, Anandh B, Chandramouli BA, Sastry Kolluri VR. Expression of p53, EGFR, pRb and bcl-2 proteins in pediatric glioblastoma multiforme: A study of 54 patients. Pediatr Neurosurg 2005;41:292-9.

[46] Suri V, Das P, Pathak P, Jain A, Sharma MC, Borkar SA, et al. Pediatric glioblastomas: A histopathological and molecular genetic study. Neuro Oncol 2009;11:274-80.

[47] Jha P, Pia Patric IR, Shukla S, Pathak P, Pal J, Sharma V, et al. Genome-wide methylation profiling identifies an essential role of reactive oxygen species in pediatric glioblastoma multiforme and validates a methylome specific for H3 histone family 3A with absence of G-CIMP/isocitrate dehydrogenase 1 mutation. Neuro Oncol 2014;16:1607-17.

[48] Jha P, Agrawal R, Pathak P, Kumar A, Purkait S, Mallik S, et al. Genome-wide small noncoding RNA profiling of pediatric high-grade gliomas reveals deregulation of several miRNAs, identifies downregulation of snoRNA cluster HBII-52 and delineates H3F3A and TP53 mutant-specific miRNAs and snoRNAs. Int J Cancer 2015;137:2343-53.

[49] Shukla B, Agarwal S, Suri V, Pathak P, Sharma MC, Gupta D, et al. Assessment of 1p/19q status by fluorescence in situ hybridization assay: A comparative study in oligodendroglial, mixed oligoastrocytic and astrocytic tumors. Neurol India 2009;57:559-66.

[50] Suri V, Jha P, Agarwal S, Pathak P, Sharma MC, Sharma V, et al. Molecular profile of oligodendrogliomas in young patients. Neuro Oncol 2011;13:1099-106.

[51] Kumar A, Pathak P, Purkait S, Faruq M, Jha P, Mallick S, et al. Oncogenic KIAA1549-BRAF fusion with activation of the MAPK/ERK pathway in pediatric oligodendrogliomas. Cancer Genet 2015;208:91-5.

[52] Kunder R, Jalali R, Sridhar E, Moiyadi A, Goel N, Goel A, et al. Real-time PCR assay based on the differential expression of microRNAs and protein-coding genes for molecular classification of formalin-fixed paraffin embedded medulloblastomas. Neuro Oncol 2013;15:1644-51.

[53] Gokhale A, Kunder R, Goel A, Sarin R, Moiyadi A, Shenoy A, et al. Distinctive microRNA signature of medulloblastomas associated with the WNT signaling pathway. J Cancer Res Ther 2010;6:521-9.

[54] Yogi K, Sridhar E, Goel N, Jalali R, Goel A, Moiyadi A, et al. MiR-148a, a microRNA upregulated in the WNT subgroup tumors, inhibits invasion and tumorigenic potential of medulloblastoma cells by targeting neuropilin 1. Oncoscience 2015;2:334-48.

[55] Panwalkar P, Moiyadi A, Goel A, Shetty P, Goel N, Sridhar E, et al. MiR-206, a cerebellum enriched miRNA is downregulated in all medulloblastoma subgroups and its overexpression is necessary for growth inhibition of medulloblastoma cells. J Mol Neurosci 2015;56:673-80.

[56] Kaur K, Kakkar A, Kumar A, Mallick S, Julka PK, Gupta D, et al. Integrating molecular subclassification of medulloblastomas into routine clinical practice: A simplified approach. Brain Pathol 2016;26:334-43.

[57] Dasgupta A, Gupta T, Pungavkar S, Shirsat N, Mahajan A, Janu A, et al. Combined clinical parameters with specific MRI features yield highly accurate prediction of medulloblastoma subtypes: Data from 72 patients in a blinded study. Neuro Oncology 2016;18:iii104-iii105.

[58] Muzumdar D, Deshpande A, Kumar R, Sharma A, Goel N, Dange N, et al. Medulloblastoma in childhood-King Edward Memorial hospital surgical experience and review: Comparative analysis of the case series of 365 patients. J Pediatr Neurosci 2011;6 Suppl 1:S78-85.

[59] Menon G, Krishnakumar K, Nair S. Adult medulloblastoma: Clinical profile and treatment results of 18 patients. J Clin Neurosci 2008;15:122-6.

[60] Gupta T, Jalali R, Goswami S, Nair V, Moiyadi A, Epari S, et al. Early clinical outcomes demonstrate preserved cognitive function in children with average-risk medulloblastoma when treated with hyperfractionated radiation therapy. Int J Radiat Oncol Biol Phys 2012;83:1534-40.

[61] Gupta T, Mohanty S, Kannan S, Jalali R. Prospective longitudinal assessment of sensorineural hearing loss with hyperfractionated radiation therapy alone in patients with average-risk medulloblastoma. Neurooncol Pract 2014;1:86-93.

[62] Biswas A, Julka PK, Bakhshi S, Suri A, Rath GK. Intracranial atypical teratoid rhabdoid tumor: Current management and a single institute experience of 15 patients from North India. Acta Neurochir (Wien) 2015;157:589-96.

[63] Biswas A, Mallick S, Purkait S, Roy S, Sarkar C, Bakhshi S, et al. Treatment outcome and patterns of failure in patients of non-pineal supratentorial primitive neuroectodermal tumor: Review of literature and clinical experience form a regional cancer center in North India. Acta Neurochir (Wien) 2015;157:1251-66.

[64] Biswas A, Mallick S, Purkait S, Gandhi A, Sarkar C, Singh M, et al. Treatment outcome and patterns of failure in patients of pinealoblastoma: Review of literature and clinical experience from a regional cancer centre in North India. Childs Nerv Syst 2015;31:1291-304.

[65] Jalali R, Gupta T, Goswami S, Golambade N, Shah N, Sarin R. Detailed Neuropsychological, Activity of Daily Living and Endocrine Function Assessment in Children with Craniopharyngioma Treated with High Precision Focal Radiotherapy: Data from a Prospective Trial. ISPNO; 2011.

[66] Jalali R, Dutta D, Kamble R, Gupta T, Munshi A, Sarin R, et al. Prospective assessment of activities of daily living using modified Barthel′s index in children and young adults with low-grade gliomas treated with stereotactic conformal radiotherapy. J Neurooncol 2008;90:321-8.

[67] Dutta D, Vanere P, Gupta T, Munshi A, Jalali R. Factors influencing activities of daily living using FIM-FAM scoring system before starting adjuvant treatment in patients with brain tumors: Results from a prospective study. J Neurooncol 2009;94:103-10.

[68] Budrukkar A, Jalali R, Dutta D, Sarin R, Devlekar R, Parab S, et al. Prospective assessment of quality of life in adult patients with primary brain tumors in routine neurooncology practice. J Neurooncol 2009;95:413-9.

[69] Jalali R, Mallick I, Dutta D, Goswami S, Gupta T, Munshi A, et al. Factors influencing neurocognitive outcomes in young patients with benign and low-grade brain tumors treated with stereotactic conformal radiotherapy. Int J Radiat Oncol Biol Phys 2010;77:974-9.

Indian data on central nervous tumors: A summary of published work

Abstract

Abstract

Keywords

References

Suggested read for related articles:

We value your privacy